Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is proud to announce the launch of its D
The Nobel Prize in Physiology or Medicine awarded
This year, the Hamburg based life sciences company
Alembic Pharmaceuticals Ltd., t
Since it’s an ingredient in so many foods, you h
Dear Readers, Welcome to the latest issue of Micr
Researcher from Queen's University, Belfast open a mystery over drug used in cardiovascular disorders and defines dug used in cardiovascular disorder may treat diabetic blindness too.
WHO reported 422 million patients with diabetes globally and loss of vision or blindness is one of the most common problem in diabetic patients. Researcher from Queen's University in collaboration with GlaxoSmithKline done this research and found that generally used cardiovascular drug named Darapladib may reduce blindness in diabetic patients when used in the form of tablets.
With our study, we show that a blood lipid produced by Lp-PLA2 constitutes a novel trigger factor in diabetic macular edema and that use of Darapladib may not only constitute a cost-effective alternative to current DMO treatments, but has the potential to be effective for patients that currently do not respond to standard treatment." Said, Dr Patric Turowski from the UCL Institute of Ophthalmology.
Story source: Queen's University
Journal References:
Paul Canning, Bridget-Ann Kenny, Vivien Price, Josephine Glenn, Mosharraf H. Sarker, Natalie Hudson, Martin Brandt, Francisco J. Lopez, David Gale, Philip J. Luthert, Peter Adamson, Patric Turowski, Alan W. Stitt. Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes. Proceedings of the National Academy of Sciences, 2016; 201514213 DOI: 10.1073/pnas.1514213113
